Description
| Description | WITHAFERIN A is a novel class of NFkappaB inhibitors, which hold promise as novel anti-inflammatory agents for treatment of various inflammatory disorders and/or cancer. |
| In vitro | WITHAFERIN A,potently inhibits NFkappaB activation by preventing the tumor necrosis factor-induced activation of IkappaB kinase beta via a thioalkylation-sensitive redox mechanism. |
| In vivo | WITHAFERIN A Displays Anti-inflammatory Properties in Vivo—Because NFκB is a critical player in the inflammatory signaling pathway and because WITHAFERIN A inhibits NFκB activation. |
| Cell Research | L929sA cells were co-treated with WITHAFERIN A and DTT for 1 h, and then TNF-induced NFκB activation was examined. |
| Animal Research | Mice are injected subcutaneously with zymosan in the footpad, and swelling is determined at several time points after the injection. Pretreatment with WITHAFERIN A(intraperitoneal) was performed to evaluate anti-inflammatory effects, whereas DEX (intraperitoneal) was chosen as a positive control. the mean of the differences between the zymosan-treated and untreated footpad for all the three groups. Both DEX. |
| Source |
| Molecular Weight |
470.6 |
| Formula | C28H38O6 |
| CAS No. | 5119-48-2 |
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 27.5 mg/mL (58.44 mM)
